Niki BioSolutions' subsidiary, DiamiR Biosciences, received NYSDOH approval to expand the specimen types for its APOE Genotyping test to include dried blood spots, plasma, and urine. This regulatory expansion allows the company to broaden its service offerings and reach a wider range of clinical and research applications, potentially increasing revenue streams.
Niki BioSolutions' subsidiary, DiamiR Biosciences, secured NYSDOH approval to expand the types of specimens that can be used for its APOE Genotyping test. This is significant because it adds dried blood spots, plasma, and urine to the previously approved blood, buccal swab, saliva, and tissue. This expansion allows DiamiR to offer its validated APOE genotyping services to a broader range of clinical and research applications, potentially increasing demand for their services and opening new revenue streams. For traders, this represents a moderate positive development, as it enhances the company's market position and potential for growth in the long term, though the immediate short-term impact on the stock price might be limited.